论文部分内容阅读
目的研究替吉奥联合奥沙利铂在晚期胃癌患者的有效性及安全性。方法病例资料来源于医院就诊的晚期胃癌患者40例,随机分为5-氟尿嘧啶组和替吉奥组,每组20例。5-氟尿嘧啶组采用5-氟尿嘧啶联合奥沙利铂治疗;替吉奥组采用替吉奥联合奥沙利铂治疗。观察比较2组患者病灶缓解率、白细胞减少等不良反应发生率、干预前和干预后患者生存质量的差异。结果替吉奥组缓解率为70.00%明显高于5-氟尿嘧啶组的50.00%(P<0.01);替吉奥组较5-氟尿嘧啶组白细胞减少等不良反应发生率低(P<0.01)。干预前2组生存质量相似,差异无统计学意义(P>0.05);干预后,替吉奥组较5-氟尿嘧啶组生存质量改善显著(P<0.05)。结论替吉奥联合奥沙利铂在晚期胃癌患者的有效性及安全性高,可有效缓解病情,降低化疗不良反应,提高患者生存质量,值得推广应用。
Objective To study the efficacy and safety of tegaserod combined with oxaliplatin in patients with advanced gastric cancer. Methods Forty patients with advanced gastric cancer were randomly divided into 5-fluorouracil group and 20 patients in each group. The 5-fluorouracil group was treated with 5-fluorouracil and oxaliplatin, while the other group was treated with tiotropium and oxaliplatin. The incidences of lesion remission, leukopenia and other adverse reactions were observed and compared between the two groups, and the differences of patients’ quality of life before and after intervention were compared. Results The response rate was 70.00% in the group of substitute gefitinib and 50.00% of the group in the 5-fluorouracil group (P <0.01). The incidence of adverse reactions such as leukopenia in the group of 5-fluorouracil was lower than that of the group of the other groups (P <0.01). The quality of life of the two groups before intervention was similar, with no significant difference (P> 0.05). After intervention, the quality of life of the two groups was significantly improved (P <0.05) compared with the 5-fluorouracil group. Conclusion The efficacy and safety of TEGO and oxaliplatin in patients with advanced gastric cancer are high, which can effectively relieve the disease, reduce the adverse reactions of chemotherapy and improve the quality of life of patients, which is worth popularizing and applying.